Ustekinumab showed longer drug survival than adalimumab and secukinumab in biologic-naive psoriasis patients in Denmark. Bimekizumab, guselkumab, and risankizumab had lower discontinuation risks in ...
On track to report interim results from approximately 25 six-month evaluable BCG-Unresponsive patients in ADVANCED-2 trial in Q1 2026Received ...
Approval is supported by data from the DEVOTE study which showed the benefit of the SPINRAZA 50 mg and 28 mg regimen in both ...
Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today highlighted pipeline ...
Pfizer shared new trial data showing its cancer drug combo helped shrink tumors more often than standard treatment in ...
Sanofi (SAN:CA) 44th Annual J.P. Morgan Healthcare Conference January 12, 2026 12:45 PM ESTCompany ParticipantsPaul Hudson - CEO & ...
The biotechnology sector offers investors a high-risk, high-reward opportunity as companies race to bring breakthrough ...
Nuvation Bio Inc. , a global oncology company focused on tackling some of the toughest challenges in cancer treatment, and Eisai Co., Ltd (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai"), a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback